Generic Name and Formulations:
Ciclopirox 8%; topical soln (nail lacquer).
Valeant Pharmaceuticals, Inc
Indications for PENLAC:
Mild to moderate onychomycosis of the fingernails and toenails (without lunula involvement) due to Trichophyton rubrum in immunocompetent patients, as part of a comprehensive management program (including professional removal of unattached, infected nails).
Apply thin layer evenly once daily over previous coat(s) to entire nail and surrounding 5mm of skin (preferably at bedtime or 8 hours before washing). If possible, apply to nail bed, hyponychium, and under surface of nail plate when it is free of the nail bed. Remove with alcohol once per week (file and trim nails while nail is free from drug). Repeat this regimen for up to 48 weeks. Improvement may take up to 6 months. Healthcare professional: Remove unattached infected nail as frequently as monthly, trim onycholytic nail, and file excess horny material.
Discontinue if sensitivity or chemical irritation occurs. Immunosuppressed or immunocompromised. HIV positive. Organ transplant recipients. Seizures. Severe plantar (moccasin) tinea pedis. Diabetes, diabetic neuropathy: consider risk of nail care before prescribing. Avoid eyes, mucous membranes. Product is flammable. Pregnancy (Cat.B). Nursing mothers.
Concomitant systemic antifungals for onychomycosis: not recommended. Do not use nail polish or other nail cosmetics on treated nails.
Rash, nail disorders (e.g., shape change, irritation, ingrown toenail, discoloration), local reactions (e.g., burning sensation, erythema).
Nail lacquer—6.6mL (w. applicator)
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|